HealthOrbit, Inc. - News Headlines

	GlaxoSmithKline Responds To British Medical Journal Article Regarding Avandia® (Rosiglitazone) (012-09.13.10)
	Allergan, Inc. Receives FDA Approval for LUMIGAN(R) 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients (014-09.13.10)
	Merck Receives Approval from FDA for Expanded Indications for Atypical Antipsychotic Medication SAPHRIS® (asenapine) Sublingual Tablets (049-09.13.10)
	New Patents Expand Coverage for Imaging and Therapeutic Applications of Peregrine's Phospholipid-Targeting Technologies (055-09.13.10)
	Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain (013-09.06.10)
	Forest Laboratories, Inc. and Gedeon Richter Plc Announce Results from a Phase II Study of Cariprazine for the Treatment of Bipolar Depression (020-09.06.10)
	CORDIS Announces Results Of Ten-Year CYPHER® Sirolimus-Eluting Coronary Stent Follow-Up (057-09.06.10)
	Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study (058-09.06.10)
	Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment (088-09.06.10)
	BRINAVESS™ (vernakalant) for Infusion Approved in the European Union for Rapid Conversion of Recent Onset Atrial Fibrillation (089-09.06.10)